Literature DB >> 22669625

New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?

Eric Raymond, Philippe Ruszniewski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22669625     DOI： 10.1007/s11523-012-0222-0

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  12 in total

Review 1.  Sunitinib in pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Pascal Hammel; Chantal Dreyer; Christian Maatescu; Olivia Hentic; Philippe Ruszniewski; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-06-02       Impact factor: 4.493

Review 2.  Relevance of angiogenesis in neuroendocrine tumors.

Authors:  Alexandre Teulé; Oriol Casanovas
Journal:  Target Oncol       Date:  2012-05-17       Impact factor: 4.493

3.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; J A Hanley; L A Johnson
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

4.  Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Authors:  Matthew H Kulke; Lillian L Siu; Joel E Tepper; George Fisher; Deborah Jaffe; Daniel G Haller; Lee M Ellis; Jacqueline K Benedetti; Emily K Bergsland; Timothy J Hobday; Eric Van Cutsem; James Pingpank; Kjell Oberg; Steven J Cohen; Mitchell C Posner; James C Yao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

9.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

10.  Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

Authors:  Eric Raymond; Sandrine Faivre; Pascal Hammel; Philippe Ruszniewski
Journal:  Target Oncol       Date:  2009-11-13       Impact factor: 4.493
View more
  1 in total

1.  Targeting neuroendocrine tumor: mixing standard options with novel therapies.

Authors:  Eric Raymond; Chantal Dreyer; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-08-24       Impact factor: 4.493
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.